Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of LDE225 in metastatic or unresectable sarcoma
ACTRN12612000533897Phase 2Completed
- Sponsor
- Australia and New Zealand Sarcoma Association
- Start
- Sep 2012
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label trial of sonidegib in Bone and soft tissue sarcoma, osteosarcoma (OS), chondrosarcoma and 3 more, sponsored by Australia and New Zealand Sarcoma Association. Started Sep 2012; status: completed.
02
Drugs
sonidegib
03
Conditions
Bone and soft tissue sarcomaosteosarcoma (OS)chondrosarcomaEwing sarcomadesmoplastic small round cell tumor (DSRCT)
Beyond the preview
Go deeper on ACTRN12612000533897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612000533897.